TY - JOUR
T1 - Zika virus vaccines
T2 - immune response, current status, and future challenges
AU - Richner, Justin M.
AU - Diamond, Michael S.
N1 - Funding Information:
This work was supported by grants from the NIH ( R01 AI073755 , R01 AI127828 , and R01 HD091218 ).
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/8
Y1 - 2018/8
N2 - Zika virus (ZIKV) is the most recent mosquito-transmitted virus to cause a global health crisis following its entrance into a naïve population in the Western Hemisphere. Once the ZIKV outbreak began investigators rapidly established small and large animal models of pathogenesis, developed a number candidate vaccines using different platforms, and defined mechanisms of protection. In this review, we characterize the adaptive immune response elicited by ZIKV infections and vaccines, the status of ongoing clinical trials in humans, and discuss future challenges within the field.
AB - Zika virus (ZIKV) is the most recent mosquito-transmitted virus to cause a global health crisis following its entrance into a naïve population in the Western Hemisphere. Once the ZIKV outbreak began investigators rapidly established small and large animal models of pathogenesis, developed a number candidate vaccines using different platforms, and defined mechanisms of protection. In this review, we characterize the adaptive immune response elicited by ZIKV infections and vaccines, the status of ongoing clinical trials in humans, and discuss future challenges within the field.
UR - http://www.scopus.com/inward/record.url?scp=85046633529&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2018.04.024
DO - 10.1016/j.coi.2018.04.024
M3 - Review article
C2 - 29753210
AN - SCOPUS:85046633529
VL - 53
SP - 130
EP - 136
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
SN - 0952-7915
ER -